Biomatics Capital
Overview
Biomatics Capital is a Seattle-based venture capital firm specializing in early-stage investments at the intersection of healthcare and technology. The firm focuses on sectors such as genomics and digital health, aiming to drive the evolution of healthcare through data-driven innovations. Biomatics Capital manages a $200 million fund, co-founded by Dr. Boris Nikolic and Julie Sunderland, who have been investing together since 2010. Their deep technical knowledge and extensive network enable them to identify and support emerging technology, healthcare, and life science ventures. The firm's investment strategy encompasses a wide range of stages, including Seed, Early Stage, Series A, Series B, Growth, Late Stage, and Pre-IPO, with investment sizes typically ranging from $1 million to $50 million. Biomatics Capital's portfolio includes companies like eGenesis, Verve Therapeutics, Omniome, and Twist Bioscience, reflecting its commitment to advancing healthcare through innovative technologies. The firm's approach combines scientific expertise with business acumen, providing portfolio companies with strategic guidance and access to a network of leading academics, pharmaceutical executives, and venture capital firms. This collaborative approach aims to create long-term successful companies with impactful strategies in the healthcare sector. Biomatics Capital's focus on transformative innovations positions it as a key player in shaping the future of healthcare and medicine, leveraging the convergence of genomics and digital data to develop superior therapeutics, diagnostics, and delivery models. By investing in cutting-edge science, the firm seeks to lower costs and improve patient outcomes, contributing to a value-based healthcare system. Through its strategic investments and partnerships, Biomatics Capital continues to play a pivotal role in advancing healthcare solutions that address critical medical needs and enhance the quality of care.
Investment Focus
- Innovative healthcare and technology solutions
- Strong management teams
- Scalable business models
- Potential for significant impact on patient outcomes
Portfolio Companies
Get the full list of 54,000+ investors
Biomatics Capital and every other firm and angel in the database — as one spreadsheet you keep.
$19one-time payment · no subscription- All 54,000+ investors — VC firms, private equity, family offices and angels
- The key person to contact at each one, with their job title
- Their work email address
- Their phone number
- Their LinkedIn profile
- Delivered as a single .xlsx file — download it as many times as you like
Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.
Frequently asked questions about Biomatics Capital
What sectors does Biomatics Capital invest in?
Biomatics Capital invests in Healthcare, Life Sciences, Digital Health, Biotechnology and Genomics, and is based in Washington, United States. Biomatics Capital is listed as a venture capital in the ConnectSafely investor database.
What stage does Biomatics Capital invest at?
Biomatics Capital backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 1M - 50M.
Which regions does Biomatics Capital invest in?
Biomatics Capital invests across United States.
What companies has Biomatics Capital invested in?
Biomatics Capital's portfolio includes Verve Therapeutics, eGenesis, Twist Bioscience and Omniome.
Last updated · Source: ConnectSafely investor database
